Acute monocytic leukemia with FLT3-ITD mutation: a case report and literature review
-
摘要: 目的:初步探讨索拉菲尼联合化疗治疗FLT3-ITD突变的复发急性单核细胞白血病后行半相合造血干细胞移植的安全性与有效性,提高对新的分子靶向治疗的认识。方法:报告1例FLT3-ITD突变的复发急性单核细胞白血病患者的临床症状、实验室特征,应用索拉菲尼联合化疗诱导治疗后进行半相合造血干细胞移植的过程。结果:患者经过索拉菲尼联合化疗后,骨髓学完全缓解,并成功进行半相合造血干细胞移植。治疗过程顺利,患者可耐受药物不良反应。结论:索拉非尼联合化疗在难治复发的FLT3-ITD阳性AML患者有一定疗效,可为该类患者行异基因造血干细胞移植提供较好时机。
-
关键词:
- 白血病,急性 /
- Fms样酪氨酸激酶3 /
- 索拉菲尼 /
- 造血干细胞,半相合
Abstract: Objective:To explore the efficacy and safety of sorafenib in combination chemotherapy followed by haploicentical hematopoietic stem cell transplantation(HSCT)for the treatment of AML with FLT3-ITD mutation,to highlight the importance of tagerting therapy.Method:We reported clinical and molecular feature and the treatment response for sorafenib in a AML patiernt with FLT3-ITD mutation.Result:The patient achieved clinical and molecular complete remission,and then successfully had haploidentical HSCT.Conclusion:Sorafenib can be safely and effectivly used in FLT3-ITD positive AML patient,which can provide right time for Allo-HSCT as soon as possible. -
-
[1] 张之南,郝玉书,赵永强,等.血液病学[M].2版.北京:人民卫生出版社,2011:732-732.
[2] LICHT J D,CHOMIENNE C,GOY A,et al.Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation(11;17)[J].Blood,1995,85:1083-1094.
[3] REGO E M,PANDOLFI P P.Analysis of the molecular genetics of acute promyelocytic leukemia in mouse models[J].Semin Hematol,2001,38:54-70.
[4] LIN R,NAGY L,INOUE S,et al.Role of the histone deacetylase complex in acute promyelocytic leukemia[J].Nature,1998,391:811-814.
[5] HE LZ,GUIDEZ F,TRIBIOLI C,et al.Distinct interactions of PML/RAR_ and PLZF/RAR_ with corepressors determine differential responses to RA in APL[J].Nat Genet,1998,18:126-134.
[6] LENGFELDER E,HOFMANN W K,NOWAK D.Impact of arsenic trioxide in the treatment of acute promyelocytic leukemia[J].Leukemia,2012,26:433-442.
[7] GHAVAMZADEH A,ALIMOGHADDAM K,GHAFFARI S H,et al.Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy[J].Ann Oncol,2006,17:131-134.
[8] MATHEWS V,GEORGE B,KAVITHA M,et al.Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia:durable remissions with minimal toxicity[J].Blood,2006,107:2627-2632.
[9] CUI X,KOBAYASHI Y,AKASHI M,et al.Metabolism and the paradoxical effects of arsenic:carcinogenesis and anticancer[J].Curr Med Chem,2008,15:2293-304.
[10] THOMAS X,TRONCY J.Arsenic:a beneficial therapeutic poison-a historical overview[J].Adler Mus Bull,2009,35:3-13.
[11] ROBOZ G L.Arsenic and old lace:novel approaches in elderly patients with acute myeloid leukemia[J].Semin Hematol,2008,45(3 Suppl 2):S22-24.
-
计量
- 文章访问数: 376
- PDF下载数: 205
- 施引文献: 0
下载: